ClinicalTrials.gg
CompletedNCT02956109Updated Jul 11, 2017

Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Volunteers

A Phase 1 interventional study of Finerenone (BAY94-8862): 1 0mg tablet and Finerenone (BAY94-8862): 5 X 0.25 mg oro-dispersible tablets in Pharmacokinetics, sponsored by Bayer. Completed at 1 site in Germany. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-07-11.

Sponsored by Bayer · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

Finerenone is developed for the treatment of diabetic kidney disease (adults) and chronic kidney disease (children). The purpose of the proposed trial is to test the pharmacokinetics of a single oral dose of finerenone (1.25 mg tablet and 5 x 0.25 mg tablets) using a novel orodispersible tablet formulation for the treatment of children, in comparison to the adult tablet formulation.

02

Conditions studied

  • Pharmacokinetics
03

In context

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male subjects
  • Age: 18 to 45 years (inclusive)
  • (BMI) : ≥ 18 and ≤ 29.9 kg/m²
  • Race: White

Exclusion criteria

Exclusion Criteria:

  • Subjects with conspicuous findings in medical history and pre-study examination in the opinion of the investigator
  • A history of relevant diseases of vital organs, of the central nervous system or other organs
  • Known renal or liver insufficiency
  • Subjects with diagnosed , psychiatric disorders, or thyroid disorders (evaluated by medical history, physical examination, clinical symptoms, and assessment of thyroid stimulating hormone at screening)
  • Medical disorder that would impair the subject's ability to complete the study in the opinion of the investigator
  • Incompletely cured pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination and effects of the study drugs will not be normal
  • Relevant diseases within the last 4 weeks prior to the first study drug administration
  • Smoking more than 10 cigarettes daily and/ or inability to refrain from smoking on the profile days until 8 h after administration
  • Vegetarian or special diets preventing the subjects from eating the standard meals during the study, especially the high-fat high-calorie American breakfast or reluctance to ingest it
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Active comparator
    Adult formulation: Finerenone tablet_Fasting

    Single oral dose of 10 mg finerenone tablet fasting

    Drug: Finerenone (BAY94-8862): 1 0mg tablet

  • Experimental
    Pediatric formulation: 5X 0.25 mg Finerenone ODT_Fasting

    Single oral dose of 5 x 0.25 mg finerenone oro-dispersible tablets fasting

    Drug: Finerenone (BAY94-8862): 5 X 0.25 mg oro-dispersible tablets

  • Experimental
    Pediatric formulation: 1.25 mg Finerenone ODT_Fasting

    Single oral dose of 1.25 mg finerenone oro-dispersible tablet fasting

    Drug: Finerenone (BAY94-8862): 1.25 mg oro-dispersible tablet

  • Experimental
    Pediatric formulation: 1.25 mg Finerenone ODT_Fed

    Single oral dose of 1.25 mg finerenone oro-dispersible tablet fed; 30 minutes after start of an American breakfast

    Drug: Finerenone (BAY94-8862): 1.25 mg oro-dispersible tablet

Interventions

06

What researchers measure

Primary outcomes

  1. Finerenone area under the plasma concentration vs. time curve (AUC)

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5. 3, 4, 6, 8, 12, 15 and 24 hours

  2. Finerenone maximum plasma concentration (Cmax)

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5. 3, 4, 6, 8, 12, 15 and 24 hours

  3. Appearance of oro-dispersible tablets assessed by questionnaire

    Time frame: Up to 5 minutes after drug administration

  4. Taste of oro-dispersible tablets assessed by questionnaire

    Time frame: Up to 5 minutes after drug administration

  5. Texture of oro-dispersible tablets assessed by questionnaire

    Time frame: Up to 5 minutes after drug administration

  6. Smell of oro-dispersible tablets assessed by questionnaire

    Time frame: Up to 5 minutes after drug administration

  7. Overall impression of oro-dispersible tablets assessed by questionnaire

    Time frame: Up to 5 minutes after drug administration

  8. Whether oro-dispersible tablets are palatable and swallowable assessed by questionnaire

    Time frame: Up to 5 minutes after drug administration

Secondary outcomes

  1. Number of patients with adverse events as a measure of safety and tolerability

    Time frame: Up to 3 weeks

07

Study locations

1 site
  • Mönchengladbach, Nordrhein-Westfalen 41061, Germany
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2016 to primary completion in Dec 2016, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2016
First posted
Nov 4, 2016
StartActual
Nov 16, 2016
Primary completionActual
Dec 22, 2016
CompletionActual
Mar 17, 2017
Last update
Jul 11, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02956109
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Nov 4, 2016
Start date
Nov 16, 2016
Primary completion
Dec 22, 2016
Completion
Mar 17, 2017
Last update
Jul 11, 2017

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Finerenone

Start the discussion